Sanofi to acquire Blueprint Medicines for $129/share plus CVRs; total equity value ~$9.1B

Blueprint Medicines Corp

Sanofi will pay $129.00 per share cash plus one CVR (up to $6) per share; total equity value ~$9.5B fully diluted.
Blueprint's Ayvakit net revenues $479M in 2024, ~$150M in Q1 2025 (+60% YoY).
Acquisition adds elenestinib (next-gen SM) and BLU-808 (wild-type KIT inhibitor); CVR milestones tied to BLU-808.
Transaction subject to regulatory approvals and tender of majority of shares; termination fees: Sanofi $500M, BPMC $318M.
Blueprint board unanimously recommends the offer.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.